Concepedia

Bengt Hamrén

BH

16

Publications

366

Citations

12

H-Index

2004

Active since

Affiliations

AstraZeneca (Sweden)(Current)

AstraZeneca (United States)

Uppsala University

AstraZeneca (United Kingdom)

Sahlgrenska University Hospital

Bengt Hamrén is an author at AstraZeneca (Sweden) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2004–2021

16

Publications

16

Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment

Bengt Hamrén, Erik Björk, Maria Sunzel et al. · Clinical Pharmacology & Therapeutics · 2008 · 66 citations

A Model for Glucose, Insulin, and Beta‐Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes

Jakob Ribbing, Bengt Hamrén, Maria Svensson et al. · The Journal of Clinical Pharmacology · 2010 · 40 citations

Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection

Yasunori Aoki, Daniel Röshammar, Bengt Hamrén et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 37 citations · Full text

Modelling and simulation to improve decision-making in clinical development

Carl‐Fredrik Burman, Bengt Hamrén, Per Olsson · Pharmaceutical Statistics · 2005 · 31 citations

, , +22

Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.

Hans Ericsson, Bengt Hamrén, Sara Bergstrand et al. · PubMed · 2004 · 28 citations

, , +14

Rows per page

1–5 of 16